| Intangibles |
|
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Licensing agreement - Paxalisib |
|
|
16,407,788 |
|
|
|
16,407,788 |
|
Less: Accumulated amortisation |
|
|
(8,877,247 |
) |
|
|
(8,335,073 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
7,530,541 |
|
|
|
8,072,715 |
|
|
|
|
|
|
|
|
|
|
Licensing agreement - EVT-801 |
|
|
9,813,362 |
|
|
|
9,813,362 |
|
Less: Accumulated amortisation |
|
|
(2,878,591 |
) |
|
|
(2,486,054 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
6,934,771 |
|
|
|
7,327,308 |
|
|
|
|
|
|
|
|
|
|
|
|
|
14,465,312 |
|
|
|
15,400,023 |
|
|
|
|
|
|
|
|
|
| Reconciliations of the written down values at the beginning and end of the current financial half-year are set out below:
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
Total |
|
|
|
$ |
|
|
$ |
|
|
$ |
|
|
|
|
7,327,308 |
|
|
|
8,072,715 |
|
|
|
15,400,023 |
|
|
|
|
(392,538 |
) |
|
|
(542,173 |
) |
|
|
(934,711 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at 31 December 2024 |
|
|
6,934,770 |
|
|
|
7,530,542 |
|
|
|
14,465,312 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|